If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ™ (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can ZEPBOUND™ (tirzepatide) be used in patients with gastroparesis?
Tirzepatide has not been studied in people with severe gastroparesis and is therefore not recommended in these patients.
See important safety information, including boxed warning, in the attached prescribing information.
Tirzepatide delays gastric emptying. This delay is largest after the first dose and diminishes over time.1
The use of tirzepatide has been associated with gastrointestinal adverse reactions, sometimes severe.1
In clinical trials, severe gastrointestinal adverse reactions were reported
- 1.7% of participants treated with tirzepatide 5 mg
- 2.5% of participants treated with tirzepatide 10 mg
- 3.1% of participants with tirzepatide 15 mg
- 1% of participants treated with placebo.1
Tirzepatide has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.1
Participants were excluded from the obesity (SURMOUNT) and type 2 diabetes (SURPASS) clinical trials if they had a known clinically significant gastric emptying abnormality such as severe gastroparesis or gastric outlet obstruction.
Enclosed Prescribing Information
1Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
Date of Last Review: November 08, 2023